Berlin biotech company leader in researching specific effective microorganisms Berlin, 4th October 2011 since its inception in 2001 by Ms. Prof. Dr. Christine lang the Berliner ORGANOBALANCE GmbH has developed into a leading and profitable working company in the study of health promoting or otherwise positively-acting lactic acid bacteria. Already in the first ten years, numerous internationally acclaimed successes were achieved as, for example, the development carried out jointly with BASF by pro-t-action, an effective against caries bacteria probiotics, or they pylori recently awarded Lonza Group, the license for the worldwide marketing of the anti-Helicobacter Lactobacillus to fight the cause of stomach ulcers.
Another milestone in the company’s history was the founding of ORGANOBALANCE medical AG in the year 2010. Finances and promotes research and development of based on specific effective micro-organisms, novel therapeutic approaches for medicines in particular and Medical devices. ORGANOBALANCE enjoys worldwide recognition for research into new applications for this novel probiotics in the fields of medicine, nutrition, animal health, agriculture, cosmetics and white biotechnology. In an anniversary event on 4th October 2011 at the Kalkscheune in Berlin high-profile speakers will pay tribute to these successes. Dr. Eric Schweitzer, President of the industrial and commerce in Berlin, congratulated the anniversary: for me, ORGANOBALANCE exemplifies how economic success can arise from the combination of scientific expertise with ingenuity, entrepreneurial ambition and hard work. ORGANOBALANCE cooperates today with many prestigious companies of various industries, achieved remarkable success year after year and sets a widely visible symbol so just in the field of life sciences.” Dr.
Stefan Marcinowski, Member of the Board of BASF SE, as well as guest of honour and keynote speaker of the evening, describes in his article the collaboration between of the two companies. Together with We have developed a caries prophylaxis ORGANOBALANCE, based on a completely new mechanism of action. Specialized research partner like ORGANOBALANCE contribute in the development of new products in the BASF with their competence and flexibility”, so Dr. Marcinowski next. Mrs Prof. Dr. long, who runs the company today, expect for the future more outstanding research results. To the competence, creativity and commitment of staff and staff will make an important contribution. The achievements of the past ten years let us look optimistically into the future”, Mrs Prof. runs long. So far, we can guess at best the entire potential of specific acting micro-organisms. Research and development in this area will deal more decades, and I’m sure that this leads us to many other ground-breaking discoveries and new product developments”, said Prof. lang to the future prospects of the company. About ORGANOBALANCE: The ORGANOBALANCE GmbH is a Companies specializing in microbial strain development. The company opens up the potential of positively-acting micro-organisms, so-called specific probiotic cultures, to errors of microflora in a natural way to balance and restore the microbial balance. Also, ORGANOBALANCE uses Saccharomyces cerevisiae yeast strains specifically for material synthesis, which are used in industrial and pharmaceutical biotechnology. Based on the proprietary master library of food suitable microorganisms, as well as the own OASSYS custom ORGANOBALANCE develops new biological products in the fields of pharmacy, preventative health care, food and cosmetics. ORGANOBALANCE was founded in 2001 and is based in Berlin.